Introduction
============

The 45% decline in global maternal deaths from 1990 to 2013[@b1-ijwh-11-309] is a deceptively rosy statistic that obscures the vast discrepancy between current morbidity and mortality rates in high- and low- to middle-income countries. The maternal mortality ratio in developing regions of the world is 14 times greater than in developed regions, and countries in sub-Saharan Africa (SSA) remain the most gravely impacted.[@b1-ijwh-11-309] Therefore, maternal and neonatal health remains a crucial field of concern in global health, particularly because the elevated incidence of maternal morbidity and mortality in low- and middle-income countries is largely preventable.[@b1-ijwh-11-309]

Cesarean section (CS) delivery is one of the most common operative procedures performed in SSA, accounting for as much as 80% of the surgical workload.[@b2-ijwh-11-309],[@b3-ijwh-11-309] In contrast to CS performed in high-income countries, CSs performed in SSA are primarily emergency operations and accompanied by high morbidity and mortality rates.[@b4-ijwh-11-309] This operation is the most important known variable associated with an increased probability of postpartum bacterial infection when compared with vaginal birth, with reported rates of infection ranging from 1% to 25%, about 5 to 20 times higher than that of vaginal delivery.[@b5-ijwh-11-309] In addition to the physical consequences associated with postpartum bacterial infection, such as maternal infirmity and neonatal mortality, these infections often share a common pathophysiological pathway with fetal and neonatal infections and death, thereby contributing to the significant social costs stemming from maternal illness.

Surgical site infections (SSIs) are an important global cause of morbidity and mortality in patients undergoing all types of operations. These infections lead to increased duration of hospitalization, health care costs, morbidity, and risk of death. Recent systematic reviews from the World Health Organization (WHO) have highlighted particularly high SSI rates in SSA.[@b6-ijwh-11-309],[@b7-ijwh-11-309] However, since these rates are derived from a mix of operative procedures, the true rate of SSI following CS is not clear, but is likely greater.

CS is of particular interest as an index procedure for SSI modeling and assessment of interventions because many of the complicating factors that may obscure the true cause of infection are not present: the surgical technique is standardized and the operation generally performed on younger women who do not suffer from the disease- and age-related risks of infection and comorbidities seen in broader surgical surveys.

The objective of this review is to create a picture of recent surgical outcomes related to CS in SSA. While there have been single- and multiple-country studies on maternal health for this region, there has been no attempt to synthesize the information across all of the countries in SSA. This kind of region- and procedure-specific information may allow for more precise design and implementation of guidelines being developed for maternal sepsis and prevention of post-CS SSIs, and can then be used by policymakers, hospital administrators, and health care workers to identify areas for improvement.

Methods
=======

We conducted a review of studies on the incidence and epidemiology of SSI following CS in SSA. PubMed (including Medline), CINAHL, Embase, and the WHO's Global Health Library were searched using the terms: ("surgical wound infection" \[MeSH\] OR surgical site infection\* \[TIAB\] OR "SSI" OR "SSIs" OR surgical wound infection\* \[TIAB\] OR surgical infection\* \[TIAB\] OR post-operative wound infection\* \[TIAB\] OR postoperative wound infection\* \[TIAB\] OR wound infection\* \[TIAB\] OR (("preoperative care" \[MeSH\] OR "preoperative care" OR "pre-operative care" OR "perioperative care" \[MeSH\] OR "perioperative care" OR "peri-operative care" OR perioperative OR intraoperative OR "perioperative period" \[MeSH\] OR "intraoperative period" \[MeSH\]) AND ("infection" \[MeSH\] OR infection \[TIAB\]))) AND ((((((((("cesarean childbirth") OR "cesarean complications") OR "cesarean delivery complications") OR "cesarean infections") OR cesarean) OR cesarean)) AND (("surgical wound infection" \[MeSH\] OR surgical site infection\* \[TIAB\] OR "SSI" OR "SSIs" OR surgical wound infection\* \[TIAB\] OR surgical infection\* \[TIAB\] OR post-operative wound infection\* \[TIAB\] OR postoperative wound infection\* \[TIAB\] OR wound infection\* \[TIAB\] OR (("preoperative care" \[MeSH\] OR "preoperative care" OR "pre-operative care" OR "Perioperative Care" \[MeSH\] OR "perioperative care" OR "peri-operative care" OR perioperative OR intraoperative OR "perioperative period" \[MeSH\] OR "intraoperative period" \[MeSH\]) AND ("infection" \[MeSH\] OR infection \[TIAB\])))))) AND ("Africa south of the Sahara" OR "sub Saharan Africa").

This search was also completed separately with individual names of countries in SSA specified by the Library of Congress. We applied the same search strategy to the Cochrane database to identify any published reviews and included references. No date restrictions were used in the search. Prospective, randomized trials were excluded, in order to eliminate studies with eligibility criteria that excluded women with conditions considered to be risk factors for SSI, as this might have confounded our analyses. References from the eligible studies were reviewed to identify additional studies.

All results from the search were independently screened, reviewed, and analyzed. Two research associates performed three levels of screening: title, abstract, and full text. Full-text articles of relevant studies were obtained and analyzed for content. Extracted data included authors, year of publication, country or countries where the study was done, study period, study setting, study population size, indications for CS, potential risk factors, reported infection prevalence or cumulative incidence data, wound-contamination class and type of SSI, antibiotic prophylaxis, and microbial isolates (if studied). Institutional review board approval was not necessary, as this was a review of previously published studies, all of which had obtained approval.

Quality assessment
------------------

To allow comparisons between individual studies, evaluate the quality of conclusions drawn from individual studies, and identify reporting gaps, we created a quality-scoring system for this review, modified from others of similar utility.[@b8-ijwh-11-309],[@b9-ijwh-11-309] The system we developed awarded one point for the reporting of each of the ten factors: study type, study dates, description of study site, HIV status, antiretroviral therapy status, preeclampsia/hypertension, antenatal care status, rupture of membranes, meconium staining, and chorioamnionitis. The same scoring system was used for the reporting of 15 operative and outcome variables: repeat CS, emergency or elective operation, cephalopelvic disproportion (CPD) or obstructed labor, fetal distress, hemorrhage, breech, type of antibiotic administered, timing of antibiotic administration, duration of operation, length of stay, Centers for Disease Control and Prevention (CDC) SSI type, endometritis, maternal death, fetal death, and duration of follow-up. The total number of categories was thus 25. As such, the rating for each could range from 0 (lowest quality) to 25 points (highest quality).

Where similar scoring systems have used categories chosen to evaluate the quality of study management and performance, our modified system is focused on evaluating how widely certain factors were reported. Investigators chose the included categories for their importance in understanding factors contributing to SSI: certain patient and operational variables are well known to increase the risk of infection, and certain definitional categories are useful in understanding the type of infection encountered.[@b12-ijwh-11-309],[@b13-ijwh-11-309] We believe that these categories outline the minimum information needed to clearly define the circumstances surrounding and leading to SSI.

Results
=======

A total of 26 studies[@b10-ijwh-11-309]--[@b35-ijwh-11-309] reporting SSI rates after CS were included in this review, representing procedures conducted on 14,063 women from 14 countries in SSA. [Table 1](#t1-ijwh-11-309){ref-type="table"} outlines the general characteristics of the eligible studies. In sum, 22 of these studies were conducted at academic and/or urban hospitals, the majority of which served as urban referral centers for smaller health care facilities. The mean city population for the hospitals was 2,376,486 with a range of 7,966--16,060,303. All eligible studies were observational. Quality scores for each study are also shown in this table. Scores ranged from 4 to 16 of a maximum of 25. Almost all studies reported the study type, study dates, and type of facility. Repeat CS, emergency or elective surgery, CPD and/or obstructed labor, and fetal distress were the most widely reported categories.

[Table 2](#t2-ijwh-11-309){ref-type="table"} shows background demographic information for the included studies and hospitals. The vast majority (76.7%) of CSs performed were emergency operations. The lowest rate of emergency CSs was 26.7% and the highest 100.0%. It was also reported that many of the hospitals saw a high number of births per year (mean 16,752, range 274--174,561), as well as a high ratio of CSs to vaginal births. The overall CS rate for women included in this review was 12.4% with a range of 1.0%--1.9%.

As shown in [Table 3](#t3-ijwh-11-309){ref-type="table"}, the most significant indication for CS in this population was CPD and/or obstructed labor (40.4%), followed by repeat CS (19.6%), fetal distress (13.0%), prolonged rupture of membranes (7.7%), breech and/or malpresentation (7.7%), eclampsia (6.6%), hemorrhage (6.3%), and cord prolapse (3.7%). CPD is likely accompanied by prolonged ruptured amniotic membranes and thus becomes a marker for contaminated procedures. Prevalence ranged 8.1%--76.9% in CPD/obstructed labor, 6.4%--44.4% for repeat CS, 2.9%--36.1% in fetal distress, 0.7%--64.9% in prolonged rupture of membranes, 3.0%--13.1% in breech and/or malpresentation, 0.6%--18.8% in preeclampsia/hypertension, 1.4%--14.4% in hemorrhage, and 1.4%--17.5% in cord prolapse.

[Table 4](#t4-ijwh-11-309){ref-type="table"} details the administration of antibiotics, widely considered a key strategy for the prevention of SSI. Only 17 of 26 total studies reported a significant proportion of women receiving antimicrobials of any kind, and only eleven studies of those 17 reported the exact antibiotic or combination of antibiotics used. There was no uniformity in either the medication given or the timing (preoperative vs postoperative) across the studies.

[Table 5](#t5-ijwh-11-309){ref-type="table"} shows the reported infectious complications categorized by definitions of infection used by the authors. Seven studies reported infection data based on standardized terminology given by the CDC. The SSI rate for these studies was 15.6%. The most widely reported SSI category, wound infection, had a cumulative incidence of 10.3%.

Discussion
==========

Efforts to reduce maternal mortality and morbidity must focus not only on expanding the quantity and availability of care but also on improving the quality of existing health care. In order to move forward with the second goal, there must be clear and accurate understanding of the current quality of care. Single-center audits are of considerable importance for both the local population and the larger population, because they can suggest improvements in reporting standards and quality of care. Given the high rates of infection, it is vital to understand past and current experiences in local health care centers in order to tailor a solution built on a foundation of good evidence. Reviews that synthesize the entire field of information are a powerful tool that can illuminate key areas for high-impact intervention and the data gaps that should be addressed.[@b8-ijwh-11-309],[@b36-ijwh-11-309]

The purpose of this review was to provide information on reported infection rates following CS in SSA. We found rates of infection ranging from 10.3% to 15.6%, many times greater than those in high-income countries, such as the US. Furthermore, the duration of follow-up was \<30 days in at least three studies, suggesting that SSI rates may have been underreported. This review also reinforced the notion that nearly all CSs in SSA are performed as emergency operations.

Our review also found CS rates of 1%--42.9%, outstripping the WHO recommendation for the optimal rate of CS, which ranges from 5% to 15% of total births.[@b37-ijwh-11-309],[@b38-ijwh-11-309] CS rates have been increasing globally,[@b38-ijwh-11-309] suggesting that the population at risk of SSI following CS in SSA will grow. In the developing world, Africa has seen the fastest pace of urban growth per year for the last 20 years (3.5%), and this rate is projected to hold steady until at least 2050. SSA is also projected to experience a faster-than-average rate of urbanization, growing from 40% of the population living in urban areas in 2014 to 56% by 2050.[@b39-ijwh-11-309] Because the facilities that offer and perform CSs are predominantly located in urban areas, they will likely have to contend with the rise in the population served. Structural and resource-based barriers to high-quality maternal health care will become more pronounced and more damaging without timely and effective intervention. Other factors that may lead to an increase in CS rates are increases in the number of theater facilities, increases in the number of surgeons, increased monitoring of labor, and the shifting trend from home deliveries to hospital deliveries.

Limitations of data
-------------------

A few limiting factors were encountered while conducting this review, most of which stemmed from limitations in individual studies. We could not capture studies or audits that were not published and/or archived, because our search was confined to databases of published studies. Internal facility reviews or audits done in smaller or more rural health care centers may not have been accessed if they were not published or uploaded to an electronic database. Additionally, the studies included in this review were nearly all from large centers located in urban areas, which likely have access to greater resources than smaller and more rural facilities. Our data thus cannot be said to be representative of the process of care or SSI rates seen at rural or smaller facilities.

A major limitation was the lack of standardized reporting across the included studies. None of the studies used identical reporting forms, and few used standard definitions for indications and infectious complication, such as SSI, endometritis, or chorioamnionitis. Seven of 26 stated that the CDC criteria for SSI were used, 18 studies used the term "wound infection" often without a specific definition, and one designated "sepsis" to describe post-CS SSI. Without corresponding diagnostic definitions, it is difficult to compare the results of individual studies. Finally, the low number of studies found was in itself a limitation, particularly given the broad search parameters. Only 26 studies representing 14 countries from a total of 52 countries in SSA were found, indicating a need for more extensive reporting.

Recommendations
===============

One category of concern highlighted by the results of this review is a relatively clear-cut and cost-effective measure: the proper administration of antibiotics. The effectiveness of antibiotic prophylaxis when administered 120 minutes or less before skin incision is established and very widely accepted.[@b40-ijwh-11-309] Broad acceptance of the use of antibiotics is reinforced by the results of this review, but there was a wide range at the time of administration, when reported. With strong evidence suggesting that the efficacy of antibiotics drops off sharply when not given within this interval, there must be a focus on the surveillance, education, and enforcement of this policy.

A second recommendation would be for authors to use standardized definitions when reporting SSI risk factors and SSI types. The unusually wide variance found within such categories as CPD/obstructed labor and PROMs suggest that the study investigators used differing definitions or classifications, which makes it difficult to compile comparable data. Regional journals can also assist by ensuring that authors uphold standard definitions where such definitions exist, such as in the SSI field.

There has been extensive reporting that a prolonged period from onset of labor to CS is a major avoidable factor contributing to maternal and neonatal morbidity and mortality.[@b41-ijwh-11-309] This delay can be broken into intervals, such as patient delay, transport delay, delay in care on admission to health care facility, and delayed operative delivery. Some factors contributing to delay are caused by cultural factors or lack of infrastructure, and will take greater time and resources to address. However, more short-term efforts may be focused on operative delays within facilities that are caused by the absence of a considered decision-making process. The current audit standard used is 30 minutes from decision to delivery in nonelective CS; however, it is unclear whether crossing this threshold truly represents a significant rise in the threat of maternal and fetal complications. Our third recommendation would be for quantitative and qualitative data on timing and factors contributing to delay to be a standard part of future studies. Finding the most feasible and reasonable decision to incision time for the SSA region would contribute greatly to improving quality of care and reduce the costs of this delay to women and facilities.

The practical method we would most recommend is the criterion-based audit, which provide a logical framework for quality improvement by systematically measuring and assessing clinical practices against previously established and accepted criteria. Criterion-based audits establish region-specific criteria for good-quality care by performing systematic literature reviews, the results of which are assessed by a panel of regional and international experts to arrive at the final audit criteria. These criteria are used to determine current practices and innovate mechanisms to achieve quality improvement. The feasibility and effectiveness of criterion-based audits in developing countries has been shown,[@b42-ijwh-11-309] and we believe that this will be an important tool in the improvement of health care and standardized reporting.

Conclusion
==========

This review of surgical site infections following cesarean section in sub-Saharan Africa found an surgical site--infection rate of 15.6% and a wound-infection rate of 10.3%.
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###### 

Study characteristics

  Study                                        Year   Study period (month/year)   Country                                                   Hospital type    Hospital city                City population (n)   Hospital county                                              Study population (n)   Quality score (n/25)
  -------------------------------------------- ------ --------------------------- --------------------------------------------------------- ---------------- ---------------------------- --------------------- ------------------------------------------------------------ ---------------------- ----------------------
  Adesunkanmi and Faleyimu[@b10-ijwh-11-309]   2003   1/1989--12/1993             Nigeria                                                   Academic         Ilesa                        647,500               Osun                                                         701                    13
  Ali[@b11-ijwh-11-309]                        1995   6/1992--9/1993              Ethiopia                                                  Academic         Jimma                        207,573               Jimma                                                        100                    12
  Amenu et al[@b12-ijwh-11-309]                2011   4/2009--3/2010              Ethiopia                                                  Academic         Jimma                        207,573               Jimma                                                        580                    10
  Ansaloni et al[@b13-ijwh-11-309]             2001   3/1997--7/1997              Kenya                                                     Rural            Kiambu                       88,869                Kiambu                                                       160                    13
  Björklund et al[@b14-ijwh-11-309]            2005   7/2001--1/2003              Uganda                                                    Urban tertiary   Kampala                      1,659,600             Kampala                                                      1,526                  16
  Brisibe et al[@b15-ijwh-11-309]              2015   NA                          Nigeria                                                   Academic         Port Harcourt                2,000,000             Rivers                                                       711                    4
  Bukar et al[@b16-ijwh-11-309]                2009   1/2001--12/2003             Nigeria                                                   Federal          Gombe                        2,353,000             Gombe                                                        250                    11
  Chilopora et al[@b17-ijwh-11-309]            2007   10/2005--12/2005            Malawi                                                    Multicenter      NA                           NA                    NA                                                           1,754                  13
  Chu et al[@b18-ijwh-11-309]                  2015   8/2010--1/2011              Burundi, Democratic Republic of the Congo, Sierra Leone   Multicenter      Masisi, Lubutu, Kabezi, Bo   NA                    North Kivu Province, Maniema, Bujumbura, Southern Province   1,276                  15
  de Nardo et al[@b19-ijwh-11-309]             2016   8/2013--11/2013             Tanzania                                                  NA               Dodoma                       410,956               Dodoma                                                       467                    11
  Ezechi et al[@b20-ijwh-11-309]               2009   1/2004--8/2008              Nigeria                                                   Urban            Lagos                        16,060,303            Lagos                                                        817                    7
  Fesseha et al[@b21-ijwh-11-309]              2011   1/2008--12/2008             Ethiopia                                                  Mixed            NA                           NA                    NA                                                           267                    12
  Harfouche et al[@b22-ijwh-11-309]            2015   1/2010--6/2010              Malawi                                                    District         Lilongwe                     1,077,116             Central Region                                               513                    11
  Jido and Garba[@b23-ijwh-11-309]             2012   1/2001--12/2002             Nigeria                                                   Academic         Kano                         3,333,300             Kano                                                         485                    12
  Johnson and Buchmann[@b24-ijwh-11-309]       2012   7/2010--8/2010              South Africa                                              Academic         Johannesburg                 4,434,817             Gauteng                                                      272                    8
  Koigi-Kamau et al[@b25-ijwh-11-309]          2005   1/2001--4/2001              Kenya                                                     District         Kiambu                       88,869                Kiambu                                                       153                    7
  Moodliar et al[@b26-ijwh-11-309]             2007   11/2003--1/2004             South Africa                                              Academic         Durban                       3,442,361             KwaZulu-Natal                                                737                    13
  Moran et al[@b27-ijwh-11-309]                1999   NA                          Ghana                                                     Rural            Techiman                     104,212               Brong Ahafo                                                  100                    10
  Morhason-Bello et al[@b28-ijwh-11-309]       2009   7/2004--9/2004              Nigeria                                                   Academic         Ibadan                       3,034,200             Oyo                                                          74                     7
  Mpogoro et al[@b29-ijwh-11-309]              2014   10/2011--2/2012             Tanzania                                                  Academic         Mwanza                       2,772,509             Mwanza                                                       345                    15
  Ojiyi et al[@b30-ijwh-11-309]                2012   6/2004--5/2008              Nigeria                                                   Academic         Orlu                         420,000               Imo                                                          385                    10
  Rabiu et al[@b31-ijwh-11-309]                2011   1/2008--12/2009             Nigeria                                                   Academic         Lagos                        16,060,303            Lagos                                                        347                    9
  Saxer et al[@b32-ijwh-11-309]                2009   12/2003--3/2004             Tanzania                                                  District         Ifakara                      99,000                Morogoro                                                     803                    8
  Sekirime and Lule[@b33-ijwh-11-309]          2008   NA                          Uganda                                                    Academic         Kampala                      1,659,600             Kampala                                                      500                    11
  van Bogaert and Misra[@b34-ijwh-11-309]      2009   NA                          South Africa                                              Public           Glen Cowie                   7,966                 Limpopo                                                      692                    6
  Zvandasara et al[@b35-ijwh-11-309]           2007   6/2006--8/2006              Kenya                                                     Academic         Harare                       1,619,000             Harare                                                       546                    12

**Abbreviation:** NA, not available.

###### 

Background

  Study                                        Hospital births per year, n   Hospital cesareans per year, n (% of total births)   Elective, n (%)   Emergency, n (%)   HIV^+^, n (%)
  -------------------------------------------- ----------------------------- ---------------------------------------------------- ----------------- ------------------ ---------------
  Adesunkanmi and Faleyimu[@b10-ijwh-11-309]   NA                            NA                                                   86 (12.3)         615 (87.7)         NA
  Ali[@b11-ijwh-11-309]                        1,236                         100 (8.1)                                            8 (8.0)           92 (91.6)          NA
  Amenu et al[@b12-ijwh-11-309]                NA                            NA                                                   23 (4.0)          557 (96.0)         NA
  Ansaloni et al[@b13-ijwh-11-309]             3,072                         242 (7.9)                                            76 (47.5)         84 (52.5)          NA
  Björklund et al[@b14-ijwh-11-309]            27,000                        5,400 (20.0)                                         34 (2.2)          1,492 (97.8)       96 (6.3)
  Brisibe et al[@b15-ijwh-11-309]              NA                            NA                                                   NA                NA                 NA
  Bukar et al[@b16-ijwh-11-309]                724                           88 (12.2)                                            69 (27.6)         180 (72.0)         NA
  Chilopora et al[@b17-ijwh-11-309]            NA                            NA                                                   452 (25.8)        1,302 (74.4)       NA
  Chu et al[@b18-ijwh-11-309]                  NA                            NA                                                   47 (3.7)          1,229 (96.3)       NA
  de Nardo et al[@b19-ijwh-11-309]             NA                            NA                                                   42 (9.0)          425 (91.0)         NA
  Ezechi et al[@b20-ijwh-11-309]               NA                            NA                                                   599 (73.3)        218 (26.7)         NA
  Fesseha et al[@b21-ijwh-11-309]              174,561                       17,145 (9.8)                                         56 (21.0)         205 (76.8)         NA
  Harfouche et al[@b22-ijwh-11-309]            14,780                        2,052 (13.9)                                         0                 513 (100)          76 (14.8)
  Jido and Garba[@b23-ijwh-11-309]             3,162                         320 (10.1)                                           51 (10.5)         434 (89.5)         NA
  Johnson and Buchmann[@b24-ijwh-11-309]       NA                            NA                                                   53 (19.5)         219 (80.5)         NA
  Koigi-Kamau et al[@b25-ijwh-11-309]          7,892                         612 (7.8)                                            11 (7.2)          141 (92.2)         13 (8.5)
  Moodliar et al[@b26-ijwh-11-309]             2,126                         744 (35.0)                                           112 (15.2)        625 (84.8)         NA
  Moran et al[@b27-ijwh-11-309]                10,000                        100 (1.0)                                            0                 100 (100)          NA
  Morhason-Bello et al[@b28-ijwh-11-309]       1,024                         296 (28.9)                                           13 (17.6)         61 (82.4)          NA
  Mpogoro et al[@b29-ijwh-11-309]              2,444                         559 (22.9)                                           26 (7.5)          319 (92.5)         NA
  Ojiyi et al[@b30-ijwh-11-309]                274                           91 (33.2)                                            166 (46.4)        192 (53.6)         NA
  Rabiu et al[@b31-ijwh-11-309]                3,569                         1,531 (42.9)                                         NA                NA                 NA
  Saxer et al[@b32-ijwh-11-309]                NA                            NA                                                   35 (10.5)         297 (89.5)         NA
  Sekirime and Lule[@b33-ijwh-11-309]          NA                            NA                                                   0                 500 (100)          NA
  van Bogaert and Misra[@b34-ijwh-11-309]      4,800                         864 (18.0)                                           189 (27.3)        503 (72.7)         NA
  Zvandasara et al[@b35-ijwh-11-309]           11,377                        2,297 (20.2)                                         130 (23.8)        414 (75.8)         NA

**Abbreviation:** NA, not available.

###### 

Indications for CS

  Study                                        Population, N   Prior CS, n (%)   PROMs, n (%)   CPD/obstructed labor, n (%)   Failed induction, n (%)   Fetal distress, n (%)   Hemorrhage, n (%)   Breech/malpresentation, n (%)   Eclampsia/Htn, n (%)   Cord prolapse, n (%)
  -------------------------------------------- --------------- ----------------- -------------- ----------------------------- ------------------------- ----------------------- ------------------- ------------------------------- ---------------------- ----------------------
  Adesunkanmi and Faleyimu[@b10-ijwh-11-309]   701             115 (16.4)        10 (1.4)       182 (26)                      21 (3)                    49 (7)                  85 (12.1)           140 (20.0)                      22 (3.1)               18 (2.6)
  Ali[@b11-ijwh-11-309]                        100             16 (16)                          44 (44)                                                 6 (6)                   8 (8)               21 (21)                         1 (1)                  
  Amenu et al[@b12-ijwh-11-309]                580                               15 (2.6)                                                                                                                                                                  
  Ansaloni et al[@b13-ijwh-11-309]             160             71 (44.4)                        47 (29.4)                     16 (10)                   28 (17.5)                                   28 (17.5)                                              28 (17.5)
  Björklund et al[@b14-ijwh-11-309]            1,526                                                                                                                                                                                                       
  Brisibe et al[@b15-ijwh-11-309]              711             201 (13.2)                       809 (53.0)                                              150 (9.8)               70 (4.6)            84 (5.5)                        103 (6.7)              
  Bukar et al[@b16-ijwh-11-309]                250                                                                                                                                                                                                         15 (2.1)
  Chilopora et al[@b17-ijwh-11-309]            1,754           18 (7.2)                         52 (20.8)                                               22 (8.8)                36 (14.4)                                           47 (18.8)              
  Chu et al[@b18-ijwh-11-309]                  1,276           452 (25.8)                       1,290 (73.5)                  60 (3.4)                  264 (15.1)              77 (4.4)            53 (3.0)                        49 (2.8)               62 (3.5)
  de Nardo et al[@b19-ijwh-11-309]             467             184 (14.4)        287 (22.5)     399 (31.3)                                              128 (10.0)              101 (7.9)                                           31 (2.4)               39 (3.1)
  Ezechi et al[@b20-ijwh-11-309]               817             166 (35.5)        11 (2.4)       81 (17.3)                                                                                                                                                  
  Fesseha et al[@b21-ijwh-11-309]              267             158 (19.3)        62 (7.6)                                                                                                                                                                  
  Harfouche et al[@b22-ijwh-11-309]            513             29 (10.9)         2 (0.7)        86 (32.2)                     8 (3.0)                   38 (14.2)               17 (6.4)            35 (13.1)                       15 (5.6)               6 (2.2)
  Jido and Garba[@b23-ijwh-11-309]             485             125 (24.4)                       113 (26.7)                                              92 (17.9)                                   48 (9.4)                                               
  Johnson and Buchmann[@b24-ijwh-11-309]       272             100                                                                                                                                                                                         
  Koigi-Kamau et al[@b25-ijwh-11-309]          153             31 (6.4)          7 (1.4)        86 (17.7)                     24 (4.9)                  19 (3.9)                7 (1.4)             48 (9.9)                        67 (13.8)              7 (1.4)
  Moodliar et al[@b26-ijwh-11-309]             737             90 (33.1)         19 (7.0)                                                                                                                                                                  
  Moran et al[@b27-ijwh-11-309]                100                               29 (19.0)                                                                                                                                                                 
  Morhason-Bello et al[@b28-ijwh-11-309]       74              101 (13.8)        3 (0.4)        154 (20.9)                                              266 (36.1)              35 (4.7)            28 (3.8)                        120 (16.3)             
  Mpogoro et al[@b29-ijwh-11-309]              345             22 (22)                          31 (31)                                                 2 (2)                   13 (13)             9 (9)                           2 (2)                  5 (5)
  Ojiyi et al[@b30-ijwh-11-309]                385                               48 (64.9)                                                                                                                                                                 
  Rabiu et al[@b31-ijwh-11-309]                347             106 (30.7)        7 (2)          28 (8.1)                                                54 (15.7)               9 (2.6)             32 (9.3)                        30 (8.7)               
  Saxer et al[@b32-ijwh-11-309]                803             43 (12)                          54 (15.1)                                               38 (10.6)               44 (12.3)                                                                  34 (9.5)
  Sekirime and Lule[@b33-ijwh-11-309]          500                                              267 (76.9)                                              68 (19.6)                                                                                          
  van Bogaert and Misra[@b34-ijwh-11-309]      692                                                                                                                                                                                                         
  Zvandasara et al[@b35-ijwh-11-309]           546                               7 (1.5)        237 (49.6)                                              14 (2.9)                26 (5.4)            8 (1.7)                         3 (0.6)                16 (3.3)
  van Bogaert and Misra[@b34-ijwh-11-309]                      156 (22.5)                                                                                                                                                                                  
  Zvandasara et al[@b35-ijwh-11-309]                           139 (22.5)        48 (8.8)                                                               16 (9.3)                                    63 (11.5)                       72 (13.2)              

**Notes:** Values in parentheses show percentage of total births. Blank cells represent data not reported in the studies.

**Abbreviations:** CS, cesarean section; PROMs, prolonged rupture of membranes; CPD, cephalopelvic disproportion; Htn, hypertension.

###### 

Perioperative factors

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                        Patients receiving antibiotics, n (%)   Antibiotic(s) used                                     Timing of antibiotics
  -------------------------------------------- --------------------------------------- ------------------------------------------------------ ------------------------------------
  Adesunkanmi and Faleyimu[@b10-ijwh-11-309]   NA                                      NA                                                     NA

  Ali[@b11-ijwh-11-309]                        Most operated cases                     NA                                                     NA

  Amenu et al[@b12-ijwh-11-309]                NA                                      NA                                                     NA

  Ansaloni et al[@b13-ijwh-11-309]             160 (100.0)                             Single-dose ampicillin 3 g-- metronidazole 500 mg IV   Immediately before operation

  Björklund et al[@b14-ijwh-11-309]            1,495 (98.0)                            Benzyl penicillin G                                    Preoperative, n (%): 346 (22.7)\
                                                                                                                                              Postoperative, n (%): 1,149 (75.3)

  Brisibe et al[@b15-ijwh-11-309]              0                                       None                                                   None

  Bukar et al[@b16-ijwh-11-309]                250 (100.0)                             NA                                                     NA

  Chilopora et al[@b17-ijwh-11-309]            1,140 (65.0)                            NA                                                     Preoperative

  Chu et al[@b18-ijwh-11-309]                  1,276 (100.0)                           Cefazolin 1 g                                          Preoperative

  de Nardo et al[@b19-ijwh-11-309]             460 (99.0)                              Ceftriaxone--metronidazole + ampicillin--cloxacillin   Preoperative, n: 10\
                                                                                                                                              Postoperative, n: 450

  Ezechi et al[@b20-ijwh-11-309]               NA                                      NA                                                     NA

  Fesseha et al[@b21-ijwh-11-309]              251 (94.0)                              NA                                                     NA

  Harfouche et al[@b22-ijwh-11-309]            424 (82.6)                              Chloramphenicol or penicillin or ceftriaxone           NA

  Jido and Garba[@b23-ijwh-11-309]             NA                                      NA                                                     NA

  Johnson and Buchmann[@b24-ijwh-11-309]       NA                                      NA                                                     NA

  Koigi-Kamau et al[@b25-ijwh-11-309]          NA                                      NA                                                     NA

  Moodliar et al[@b26-ijwh-11-309]             725 (98.0)                              NA                                                     NA

  Moran et al[@b27-ijwh-11-309]                NA                                      NA                                                     NA

  Morhason-Bello et al[@b28-ijwh-11-309]       74 (100.0)                              NA                                                     NA

  Mpogoro et al[@b29-ijwh-11-309]              344 (99.7)                              Single-dose ampicillin or nonampicillin combination    NA

  Ojiyi et al[@b30-ijwh-11-309]                358 (100.0)                             Ampicillin--cloxacillin or metronidazole--gentamicin   Preoperative

  Rabiu et al[@b31-ijwh-11-309]                NA                                      NA                                                     NA

  Saxer et al[@b32-ijwh-11-309]                524 (99.0)                              Chloramphenicol, aminopenicillin, benzylpenicillin     Preoperative, n (%): 63 (12.0)\
                                                                                                                                              Postoperative, n (%): 461 (88.0)

  Sekirime and Lule[@b33-ijwh-11-309]          478 (100.0)                             Penicillin                                             Postoperative

  van Bogaert and Misra[@b34-ijwh-11-309]      692 (100.0)                             Ceftriaxone 1 g IV                                     Post--cord clamping

  Zvandasara et al[@b35-ijwh-11-309]           546 (100.0)                             Penicillin--chloramphenicol                            Preoperative
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Values in parentheses show percentage of total births.

**Abbreviation:** NA, not available.

###### 

Postoperative complications

  Study                                        Population, N   SSI[\*](#tfn7-ijwh-11-309){ref-type="table-fn"}, n (%)   Superficial, n (%)   Deep, n (%)   Organ/space, n (%)   Wound infection, n (%)   Sepsis/febrile morbidity, n (%)   Endometritis, n (%)   Maternal death, n (%)   Perinatal death or stillbirth, n (%)   Follow-up (days), n
  -------------------------------------------- --------------- -------------------------------------------------------- -------------------- ------------- -------------------- ------------------------ --------------------------------- --------------------- ----------------------- -------------------------------------- ---------------------
  Adesunkanmi and Faleyimu[@b10-ijwh-11-309]   701                                                                                                                              138 (19.7)               115 (16.4)                                                                      15 (2.1)                               
  Ali[@b11-ijwh-11-309]                        100                                                                                                                              27 (27.0)                21 (21.0)                         33 (33.0)                                                                            
  Amenu et al[@b12-ijwh-11-309]                580             66 (11.4)                                                                                                                                                                                                                                                        
  Ansaloni et al[@b13-ijwh-11-309]             160                                                                                                                              21 (13.1)                7 (4.4)                                                                         10 (6.3)                               42
  Björklund et al[@b14-ijwh-11-309]            1,526                                                                                                                            99 (6.5)                                                   170 (11.1)                                                                           
  Brisibe et al[@b15-ijwh-11-309]              711             96 (13.5)                                                26 (3.7)             44 (6.2)      26 (3.7)                                                                                                                                                             
  Bukar et al[@b16-ijwh-11-309]                250                                                                                                                              11 (4.4)                 4 (1.6)                                                 2 (0.8)                 19 (7.6)                               
  Chilopora et al[@b17-ijwh-11-309]            1,754                                                                                                                            151 (8.6)                444 (25.3)                                              23 (1.3)                234 (13.3)                             7
  Chu et al[@b18-ijwh-11-309]                  1,276           93 (7.3)                                                 85 (6.7)             7 (0.5)                                                                                                             7 (0.5)                 174 (13.6)                             
  de Nardo et al[@b19-ijwh-11-309]             467             225 (48.2)                                               138 (29.6)           69 (14.8)     5 (1.1)                                                                                                                                                              30
  Ezechi et al[@b20-ijwh-11-309]               817                                                                                                                              76 (9.3)                                                                                                                                        5
  Fesseha et al[@b21-ijwh-11-309]              267                                                                                                                              20 (7.5)                                                                         2 (0.7)                                                        
  Harfouche et al[@b22-ijwh-11-309]            513                                                                                                                              1 (0.2)                                                                                                  63 (12.3)                              
  Jido and Garba[@b23-ijwh-11-309]             485             44 (9.1)                                                                                                                                                                                                                                                         
  Johnson and Buchmann[@b24-ijwh-11-309]       272                                                                                                                              30 (11.0)                4 (1.5)                                                                                                                14
  Koigi-Kamau et al[@b25-ijwh-11-309]          153                                                                                                                              29 (5.3)                                                                                                                                        
  Moodliar et al[@b26-ijwh-11-309]             737                                                                                                                              39 (5.3)                                                   19 (2.6)                                                                             
  Moran et al[@b27-ijwh-11-309]                100                                                                                                                              25 (25.0)                                                                        4 (4.0)                                                        
  Morhason-Bello et al[@b28-ijwh-11-309]       74                                                                                                                               12 (16.2)                                                                                                                                       
  Mpogoro et al[@b29-ijwh-11-309]              345             34 (9.9)                                                 21 (6.1)             8 (2.3)       5 (1.4)                                                                                                                                                              30
  Ojiyi et al[@b30-ijwh-11-309]                385                                                                                                                              41 (11.5)                30 (8.4)                                                3 (0.8)                                                        
  Rabiu et al[@b31-ijwh-11-309]                347                                                                                                                              47 (13.5)                69 (19.9)                         9 (2.6)               3 (0.9)                                                        
  Saxer et al[@b32-ijwh-11-309]                803             125 (23.7)                                               54 (10.2)            54 (10.2)     15 (2.8)                                                                                              16 (3.0)                                                       
  Sekirime and Lule[@b33-ijwh-11-309]          500                                                                                                                              77 (16.1)                                                                                                                                       
  van Bogaert and Misra[@b34-ijwh-11-309]      692                                                                                                                                                       51 (7.4)                                                                                                               
  Zvandasara et al[@b35-ijwh-11-309]           546                                                                                                                              99 (18.1)                77 (14.1)                         122                                                                                  

**Notes:**

As per Centers for Disease Control and Prevention. Values in parentheses show percentage of total births. Blank cells represent data not reported in the studies. In this table, the included studies used varying definitions for SSI/wound infections, so it was not possible to aggregate data under one category/definition.

**Abbreviation:** SSI, surgical site infection.
